A subsidiary of Johnson & Johnson, Janssen is a Belgian pharmaceutical company which announced in January 2021 that its single-dose COVID-19 vaccine is 66% effective. As a single-dose jab, the vaccine would be easier to roll out than existing vaccines, and could help boost the international vaccination effort. While the vaccine has yet to be approved by regulators, the UK has already pre-ordered 30 million doses.<\/p>
Janssen Pharmaceuticals is a pharmaceutical company that researches medical disorders, such as mental illness, neurological disorders and gastrointestinal disorders, for the development of new drugs. Janssen is one of the companies that has created a vaccine for COVID-19, having received $456 million (\u00a3342 million) from the U.S. Biomedical Advanced Research and Development Authority.<\/p>\n\n
It\u2019s possible to invest in Janssen Pharmaceuticals, but as it\u2019s owned by Johnson & Johnson, you\u2019d need to buy Johnson & Johnson shares.<\/p>\n\n
This means that if you choose to invest in Janssen by buying shares in Johnson & Johnson, then you\u2019ll be investing in the other brands that it owns as well. Research all of the brands above and other brands that Johnson & Johnson owns to get a full picture of the company.<\/p>\n
\n\n